THERE ARE NO GUARANTEES IN LIFE, SO YOU JUST TAKE YOUR BEST SHOT. IN THE PAST I RECOMMENDED TWO STOCK, LFVN AND IDWAF (WHICH HAS SINCE BEEN ACQUIRED) BOTH APPRECIATED OVER 400%.
I WRITE ABOUT THESE OPPORTUNITIES RARELY, AND ONLY TWICE. SO THIS IS IT FOLKS
HELIUS MEDICAL TECHNOLOGIES I BELIEVE WILL APPRECIATE UP TO AND OVER 1000% DUE TO THEIR DEVICE THAT WILL EVENTUALLY HELP MILLIONS OF PEOPLE GLOBALLY. THE RESULTS IN THE TRIALS HAVE BEEN NOTHING SHORT OF AMAZING.
SO THIS IS IT, HSDT IS AT A VERY ATTRACTIVE PRICE NOW, OR YOU CAN WAIT AND PAY $20 A SHARE IN A FEW MONTHS)))
Helius Medical Technologies and HealthTech Connex Announce Alliance to Build Canadian Commercial Infrastructure
NEWTOWN, Pa., Oct. 02, 2018 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that the Company has entered into an agreement with HealthTech Connex, Inc. (“HTC”) to develop and manage neuroplasticity clinics in Canada.
“We are excited to announce this strategic alliance with HealthTech Connex and look forward to establishing our commercial infrastructure in Canada,” said CEO Philippe Deschamps. “This new agreement with HTC will result in the formation of a new operating entity called Heuro Canada and is the first step towards our shared goal of giving hope to people with Traumatic Brain Injury by ensuring that our novel therapy will be accessible to Canadians once cleared by the regulatory authorities.”
“The agreement to establish Heuro Canada is an important step in establishing the commercial infrastructure for both the PoNS™ Treatment and the NeuroCatch™ Platform measurement in Canada,” said Kirk Fisher, CEO of HealthTech Connex. “Heuro Canada will establish two neuroplasticity clinics here in Canada, initially, as we consider future expansion. We look forward to the possibility of expanding our commercial infrastructure through the newly formed Heuro Canada venture.”
Both the Portable Neuromodulation Stimulator (PoNS™) device and the NeuroCatch™ Platform are currently investigational devices, not for sale in Canada or the US. PoNS was submitted for review by Health Canada on September 27th, 2018 and the NeuroCatch™ Platform is planned to be submitted to Health Canada in Q1 of 2019. Both technologies will be used in Heuro Canada neuroplasticity clinics only if and when those technologies are cleared for use in Canada by Health Canada. Subject to the foregoing, Heuro Canada is anticipated to be operational in the fourth quarter of 2018.
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company’s first product in development is the Portable Neuromodulation Stimulator (PoNS). For more information, visit www.heliusmedical.com.
About the PoNS Device and PoNS Treatment
PoNS Treatment is the first and only tongue-delivered neuromodulation that combines stimulation of cranial nerves with physical and cognitive therapy to restore lost neurological function. The Portable Neuromodulation Stimulator (PoNS) is an investigational, non-invasive, medical device that delivers stimulation to the cranial nerves.
The Company’s trials investigating the PoNS in traumatic brain injury are more fully discussed in the Company’s disclosure materials, including its Annual Report on Form 10-K and other filings with the United States Securities and Exchange Commission.